George W. Bush headlines $26 million fundraiser for Inova

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Former President George W. Bush and former White House advisor Karl Rove helped raise more than $26 million for the Inova Schar Cancer Institute, setting a new record for a single-event non-profit fundraiser in the Washington, D.C., region.

The donations will help support a new highly personalized cancer research and treatment center on a 117-acre campus.

The fundraising dinner, held at the Inova Center for Personalized Health and chaired by NVR, Inc. president and chief executive officer Paul Saville and his wife Linda, drew more than 225 guests.

Former President Bush, who was interviewed by his former advisor at the event, has made the fight against cancer one of the priorities of his post-presidential activities.

The Inova Schar Cancer Institute got its start in 2015, when Dwight Schar, Chairman of the Board of NRV Inc., and his wife Martha, made a $50 million gift to Inova, the largest in the health system’s history. The institute will move into a new facility on the campus of the Inova Center for Personalized Health in Falls Church, Virginia, in April 2019.

YOU MAY BE INTERESTED IN

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login